Doesn't seem to be reflected in today's trading volume of $2,059...

Doesn't seem to be reflected in today's trading volume of $2,059 worth of shares! I like the company's prospects but my questions marks at the moment are:

• how big is the actual addressable mark vs their projections. Their US sales are small and not growing particularly quickly. Is it their market penetration in terms of optometrists or the number of products they offer which needs to be addressed to improve the revenue growth quickly?
• how aware of the problem is the market and is there a sense of urgency in the "addressable market" to fix the issue or is it only raised by the worst cases who need to seek clinical outcomes?
• How price competitive and sticky is there product? If inflation kicks in as some are projecting will they be able to pass on their costs to the consumer and will people continue to use the product or will they look for cheaper alternatives?
• What is the cost benefit between their products and other alternatives now and in the future? Other lenses, surgery etc.

I guess we will see the progress in Europe and in terms of their new product launches by early to mid next year. Still a lot which needs to be done to turn this one into a winner.